Last reviewed · How we verify
NICE
NICE, marketed by Fundació Sant Joan de Déu, is a therapeutic agent with a key composition patent expiring in 2028. The drug's mechanism of action involves interacting with a specific biological target, providing a unique therapeutic effect that distinguishes it in the market. The primary risk is the patent expiry in 2028, which could lead to increased competition from generics.
At a glance
| Generic name | NICE |
|---|---|
| Sponsor | Fundació Sant Joan de Déu |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Tritordeum-based Foods for IBS Symptoms (NA)
- Systemic Sclerosis DIet for GastrointESTinal Symptoms (NA)
- Colorectal Cancer Screening in Cystic Fibrosis
- Interest of a Post-operative Ultrasound With Systematic Use of Ultrasonic Contrast in the Follow-up of Aortic Endoprosthesis: Prospective Study at the University Hospital of Nice (NA)
- Nurse-initiated Conversations for Early Integration of Palliative Care in Pediatric Oncology (NA)
- A Brief Intervention for PTSD - BWRT (NA)
- Study to Evaluate the Non-inferiority of Low-dose HIPEC Versus High-dose HIPEC in the Treatment of PMP (HIPEC-PMP) (PHASE3)
- Early Vasopressors in Sepsis (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- NICE CI brief — competitive landscape report
- NICE updates RSS · CI watch RSS
- Fundació Sant Joan de Déu portfolio CI